NCT05503875View on ClinicalTrials.gov

Immunoclassification of Psoriasis: a Strategy for Precision Medicine

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
ImmunoclassificationPsoriasis
Interventions
BIOLOGICAL

adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate

Psoriasis patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.

Trial Locations (1)

310000

RECRUITING

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER